Abstract
Background: CYP1A2 and CYP2A6 are polymorphic enzymes that metabolise several compounds of clinical importance. This study investigated the prevalent phenotypes of these enzymes and the influence of age and sex on enzyme activity in a Nigerian population.
Methods: Caffeine (110 mg) was administered to each of 129 healthy, unrelated subjects (85 males and 44 females) who were non-smokers. Urine voided within 7 h after caffeine administration was collected for a high performance liquid chromatographic assay of caffeine (137X), 1,7-dimethyluric acid (17U) and 1,7-dimethylxanthine (17X). CYP1A2 activity was measured as a ratio of (17U+17X) to 137X, while 17U/17X served as marker for CYP2A6. Transformed data were analysed and the influences of age and sex on activity were also determined.
Results: Distribution of CYP1A2 activity in the population was bimodal with a mean±SD of 0.82±0.41, while that of CYP2A6 was trimodal with a mean±SD activity of 0.27±0.42 of the log-transformed urinary molar ratio of metabolites. The influences of age and sex on enzyme activity for both CYP1A2 and CYP2A6 were not significant (p>0.05).
Conclusions: The study established the prevalence of polymorphism in phenotypes of CYP1A2 and CYP2A6 activity in the Nigerian population, but no influence of age and sex on enzyme activity was observed in this population.
References
1. Campbell MC, Tishkoff SA. African genetic diversity: implications for human demographic history, modern human origins, and complex disease mapping. Annu Rev Genomics Hum Genet 2008;9:403–33.10.1146/annurev.genom.9.081307.164258Search in Google Scholar PubMed PubMed Central
2. Xu P, Huang S, Zhu R, Han X, Zhou H. Phenotypic polymorphism of CYP2A6 activity in a Chinese population. Eur J Clin Pharmacol 2002;58:333–7.10.1007/s00228-002-0480-3Search in Google Scholar PubMed
3. Thorna CF, Aklillu E, Kleina TE, Altmana RB. PharmGKB summary: very important pharmacogene information for CYP1A2. Pharmacogenet Genomics 2012;22:73–7.10.1097/FPC.0b013e32834c6efdSearch in Google Scholar PubMed PubMed Central
4. Laika B, Leucht S, Heres S, Schneider H, Steimer W. Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome. Pharmacogenomics J 2010;10:20–9.10.1038/tpj.2009.32Search in Google Scholar PubMed
5. Jaquenoud SE, Knezevic B, Morena GP, Harenberg S, Oneda B, Crettol S, et al. ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine. J Clin Psychopharmacol 2009;29:319–26.10.1097/JCP.0b013e3181acc372Search in Google Scholar PubMed
6. B’chir F, Pavanello S, Knani J, Boughattas S, Arnaud MJ, Saguem S. CYP1A2 polymorphisms and adenocarcinoma lung cancer risk in Tunisian population. Life Sci 2009;84:779–84.10.1016/j.lfs.2009.03.008Search in Google Scholar PubMed
7. Akopyan G, Bonavida B. Understanding tobacco smoke carcinogen NNK and lung tumorigenesis. Int J Oncol 2006;29:745–52.10.3892/ijo.29.4.745Search in Google Scholar
8. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414–23.Search in Google Scholar
9. Audrain-McGovern J, Al Koudsi N, Rodriguez D, Wileyto EP, Shields PG, Tyndale RF. The role of CYP2A6 in the emergence of nicotine dependence in adolescents. Pediatr 2007;119:264–74.10.1542/peds.2006-1583Search in Google Scholar PubMed
10. Canova C, Hashibe M, Simonato L, Nelis M, Metspalu A, Lagiou P, et al. Genetic associations of 115 polymorphisms with cancers of the upper aerodigestive tract across 10 European countries: the ARCAGE project. Cancer Res 2009;69:2956–65.10.1158/0008-5472.CAN-08-2604Search in Google Scholar PubMed
11. Upadhyaya P, Hecht SS. Identification of adducts formed in the reactions of 5′-acetoxy- N′-nitrosonornicotine with deoxyadenosine, thymidine, and DNA. Chem Res Toxicol 2008;21:2164–71.10.1021/tx8002559Search in Google Scholar PubMed PubMed Central
12. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013;138: 103–41.10.1016/j.pharmthera.2012.12.007Search in Google Scholar PubMed
13. Teekachunhatean S, Tosri N, Rojanasthien N, Srichairatanakool S, Sangdee C. Pharmacokinetics of caffeine following a single administration of coffee enema versus oral coffee consumption in healthy male subjects. ISRN Pharmacol 2013;2013:147238.10.1155/2013/147238Search in Google Scholar PubMed PubMed Central
14. Carrillo JA, Christensen M, Ramos SI, Alm C, Dahl ML, Benitez J, et al. Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine. Ther Drug Monit 2000;22:409–17.10.1097/00007691-200008000-00008Search in Google Scholar PubMed
15. Muscat J, Pittman B, Kleinman W, Lazarus P, Stellman S, Richie J. Comparison of CYP1A2 and NAT2 phenotypes between Black and White smokers. Biochem Pharmacol 2008;76:929–37.10.1016/j.bcp.2008.07.024Search in Google Scholar PubMed PubMed Central
16. Jack DB. Statistical analysis of polymorphic drug metabolism data using the Rosin Rammler Sperling Weibull distribution. Eur J Clin Pharmacol 1983;25:443–8.10.1007/BF00542108Search in Google Scholar PubMed
17. Tang BK, Zhou Y, Kadar D, Kalow W. Caffeine as a probe for CYP1A2 activity: potential influence of renal factors on urinary phenotypic trait measurements. Pharmacogenetics 1994;4: 117–24.10.1097/00008571-199406000-00002Search in Google Scholar
18. Peterson S, Schwarz Y, Li SS, Li L, King IB, Chen C, et al. CYP1A2, GSTM1, and GSTT1 Polymorphisms and diet effects on CYP1A2 activity in a crossover feeding trial. Cancer Epidemiol Biomarkers 2009;18:3118–25.10.1158/1055-9965.EPI-09-0589Search in Google Scholar PubMed PubMed Central
19. Hamdy SI, Hiratsuka M, Narahara K, Endo N, El-Enany M, Moursi N, et al. Genotyping of four genetic polymorphisms in the CYP1A2 gene in the Egyptian population. Br J Clin Pharmacol 2002;55:321–4.10.1046/j.1365-2125.2003.01787.xSearch in Google Scholar PubMed PubMed Central
20. Butler MA, Lang NP, Young JF, Caporaso NE, Vineis P, Hayes RB, et al. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 1992;2:116–27.10.1097/00008571-199206000-00003Search in Google Scholar PubMed
21. Ou-Yang D, Huang S, Wang W, Xie H, Xu Z, Shu Y, et al. Phenotypic polymorphism and gender-related differences of CYP1A2 activity in a Chinese population. Br J Clin Pharmacol 2000;49:145–51.10.1046/j.1365-2125.2000.00128.xSearch in Google Scholar PubMed PubMed Central
22. Browning SL, Tarekegn A, Endashaw, Bekele E, Bradman N, Thomas MG. CYP1A2 is more variable than previously thought: a genomic biography of the gene behind the human drug-metabolizing enzyme. Pharmacogenet Genomics 2010;20: 647–64.10.1097/FPC.0b013e32833e90ebSearch in Google Scholar PubMed
23. Dandara C, Swart M, Mpeta B, Wonkam A. Cytochrome P450 pharmacogenetics in African populations:implications for public health. Expert Opin Drug Metab Toxicol 2014;10:769–85.10.1517/17425255.2014.894020Search in Google Scholar PubMed
24. Jiang Z, Dragin N, Jorge-Nebert LF, Martin MV, Guengerich FP, Aklillu E. Search for an association between the human CYP1A2 genotype and CYP1A2 metabolic phenotype. Pharmacogenet Genomics 2006;16:359–67.10.1097/01.fpc.0000204994.99429.46Search in Google Scholar PubMed
25. Klein K, Winter S, Turpeinen M, Schwab M, Zanger UM. Pathway-targeted pharmacogenomics of CYP1A2 in human liver. Front Pharmacol 2010;2:129.10.3389/fphar.2010.00129Search in Google Scholar PubMed PubMed Central
26. Ilett KF, Castleden WM, Vandongen YK, Stacey MC, Butler MA, Kadlubar FF. Acetylation phenotype and cytochrome P450 1A2 phenotype are unlikely to be associated with peripheral arterial disease. Clin Pharmacol Ther 1993;54:317–22.10.1038/clpt.1993.153Search in Google Scholar PubMed
27. Nakajima M, Yokoi T, Mizutani M, Shin S, Kadlubar FF, Kamataki T. Phenotyping of CPY1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene. Cancer Epidemiol Boimarkers Prev 1994;3:413–21.Search in Google Scholar
28. Fujita K, Yamamoto W, Endo S, Endo H, Nagashima F, Ichikawa W, et al. CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1. Cancer Sci 2008;99: 1049–54.10.1111/j.1349-7006.2008.00773.xSearch in Google Scholar PubMed
29. Di Iulio J, Fayet A, Arab-Alameddine M, Rotger M, Lubomirov R, Cavassini M, et al. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet Genomics 2009;19:300–9.10.1097/FPC.0b013e328328d577Search in Google Scholar PubMed
30. Djordjevic N, Carrillo JA, van den Broek MP, Kishikawa J, Roh HK, Bertilsson L, et al. Comparisons of CYP2A6 genotype and enzyme activity between Swedes and Koreans. Drug Metab Pharmacokinet 2013;28:93–7.10.2133/dmpk.DMPK-12-RG-029Search in Google Scholar
31. Aklillu E, Djordjevic N, Carrillo JA, Makonnen E, Bertilsson L, Ingelman-Sundberg M. High CYP2A6 enzyme activity as measured by a caffeine test and unique distribution of CYP2A6 variant alleles in Ethiopian population. OMICS 2014;18:446–53.10.1089/omi.2013.0140Search in Google Scholar PubMed PubMed Central
32. Djordjevic N, Carrillo A, Gervasini G, Jankovic S, Aklillu E. In vivo evaluation of CYP2A6 and xanthine oxidase enzyme activities in the Serbian population. Eur J Clin Pharmacol 2010;66:571–8.10.1007/s00228-010-0785-6Search in Google Scholar PubMed
33. Relling MV, Lin JS, Ayers GD, Evans WE. Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clin Pharmacol Ther 1992;52:643–58.10.1038/clpt.1992.203Search in Google Scholar PubMed
34. Sinues B, Fanlo A, Mayayo E, Carcas C, Vicente J, Arenaz I, et al. CYP2A6 activity in a healthy Spanish population:effect of age, sex, smoking, and oral contraceptives. Hum Exp Toxicol 2008;27:367–72.10.1177/0960327107082224Search in Google Scholar PubMed
©2015 by De Gruyter
